Heidi Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Australian AI clinical documentation platform. Used by Monash Health (1.6M patients). $96.6M raised ($65M Series B at $465M valuation). Founded 2019, Melbourne.
About
Heidi Health was founded in 2019 in Melbourne, Australia by Dr. Thomas Kelly and Ryan Wright to eliminate the administrative burden of clinical documentation for healthcare providers. Clinicians spend 30–50% of working hours on documentation — typing notes, generating referral letters, completing forms — time that could otherwise go to patient care. Heidi built an ambient AI documentation platform that listens to patient consultations, transcribes in real time, and automatically generates structured clinical notes and referral letters tailored to each clinician's specialty.\n\nThe platform integrates with major EHR systems to push completed notes directly into patient charts, eliminating copy-paste friction. The AI engine supports general practice, specialist medicine, allied health, and nursing, and learns each clinician's personal documentation style over time to reduce editing effort. Heidi is deployed at Monash Health in Victoria, one of Australia's largest public health networks serving 1.6 million patients, as a flagship enterprise reference deployment.\n\nHeidi Health has raised $96.6 million in total funding, including a $65 million Series B at a $465 million valuation. The company is one of the fastest-growing clinical documentation AI platforms in Australia and is expanding internationally. As health systems globally address clinician burnout driven by documentation load, ambient AI documentation is emerging as a high-ROI technology investment, positioning Heidi Health alongside US-based competitors including Nuance DAX and Suki.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.